Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/INSR_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/INSR_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/INSR_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/INSR_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/INSR_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/INSR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/INSR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/INSR_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000918522 | Liver | HCC | ribonucleoside diphosphate metabolic process | 72/7958 | 106/18723 | 1.05e-07 | 2.03e-06 | 72 |
GO:004603122 | Liver | HCC | ADP metabolic process | 63/7958 | 90/18723 | 1.17e-07 | 2.25e-06 | 63 |
GO:000913522 | Liver | HCC | purine nucleoside diphosphate metabolic process | 70/7958 | 103/18723 | 1.52e-07 | 2.82e-06 | 70 |
GO:000917922 | Liver | HCC | purine ribonucleoside diphosphate metabolic process | 70/7958 | 103/18723 | 1.52e-07 | 2.82e-06 | 70 |
GO:000913222 | Liver | HCC | nucleoside diphosphate metabolic process | 81/7958 | 124/18723 | 2.34e-07 | 4.17e-06 | 81 |
GO:000610921 | Liver | HCC | regulation of carbohydrate metabolic process | 109/7958 | 178/18723 | 3.36e-07 | 5.78e-06 | 109 |
GO:004693922 | Liver | HCC | nucleotide phosphorylation | 68/7958 | 101/18723 | 3.95e-07 | 6.70e-06 | 68 |
GO:000616522 | Liver | HCC | nucleoside diphosphate phosphorylation | 66/7958 | 99/18723 | 1.01e-06 | 1.52e-05 | 66 |
GO:000609622 | Liver | HCC | glycolytic process | 56/7958 | 81/18723 | 1.11e-06 | 1.65e-05 | 56 |
GO:00518172 | Liver | HCC | modulation of process of other organism involved in symbiotic interaction | 56/7958 | 81/18723 | 1.11e-06 | 1.65e-05 | 56 |
GO:00109062 | Liver | HCC | regulation of glucose metabolic process | 76/7958 | 119/18723 | 2.03e-06 | 2.79e-05 | 76 |
GO:000675722 | Liver | HCC | ATP generation from ADP | 56/7958 | 82/18723 | 2.06e-06 | 2.83e-05 | 56 |
GO:004578711 | Liver | HCC | positive regulation of cell cycle | 172/7958 | 313/18723 | 5.29e-06 | 6.58e-05 | 172 |
GO:0048285 | Liver | HCC | organelle fission | 254/7958 | 488/18723 | 1.07e-05 | 1.23e-04 | 254 |
GO:00106752 | Liver | HCC | regulation of cellular carbohydrate metabolic process | 88/7958 | 146/18723 | 1.08e-05 | 1.24e-04 | 88 |
GO:003582111 | Liver | HCC | modulation of process of other organism | 67/7958 | 106/18723 | 1.34e-05 | 1.48e-04 | 67 |
GO:004347021 | Liver | HCC | regulation of carbohydrate catabolic process | 39/7958 | 56/18723 | 3.63e-05 | 3.61e-04 | 39 |
GO:004311221 | Liver | HCC | receptor metabolic process | 96/7958 | 166/18723 | 4.69e-05 | 4.50e-04 | 96 |
GO:004426221 | Liver | HCC | cellular carbohydrate metabolic process | 153/7958 | 283/18723 | 5.27e-05 | 5.00e-04 | 153 |
GO:000689821 | Liver | HCC | receptor-mediated endocytosis | 134/7958 | 244/18723 | 5.73e-05 | 5.31e-04 | 134 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
INSR | SNV | Missense_Mutation | | c.3652N>C | p.Asp1218His | p.D1218H | P06213 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
INSR | SNV | Missense_Mutation | | c.3556N>C | p.Glu1186Gln | p.E1186Q | P06213 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
INSR | SNV | Missense_Mutation | | c.2585N>C | p.Phe862Ser | p.F862S | P06213 | protein_coding | tolerated(0.88) | benign(0) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
INSR | SNV | Missense_Mutation | | c.1889N>T | p.Ser630Leu | p.S630L | P06213 | protein_coding | deleterious(0.01) | possibly_damaging(0.459) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
INSR | SNV | Missense_Mutation | | c.487N>G | p.Ile163Val | p.I163V | P06213 | protein_coding | tolerated(0.06) | benign(0.123) | TCGA-D8-A13Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
INSR | SNV | Missense_Mutation | | c.2072C>G | p.Ser691Cys | p.S691C | P06213 | protein_coding | tolerated(0.06) | benign(0.005) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
INSR | insertion | In_Frame_Ins | novel | c.2752_2753insTGGCACAATCTCAGCTCACTGTAGCCTCCGCCTCCCGGGTTCAAG | p.Pro918delinsLeuAlaGlnSerGlnLeuThrValAlaSerAlaSerArgValGlnAla | p.P918delinsLAQSQLTVASASRVQA | P06213 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
INSR | insertion | Frame_Shift_Ins | novel | c.1227_1228insAGAAAATGTATTGA | p.Leu412CysfsTer8 | p.L412Cfs*8 | P06213 | protein_coding | | | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
INSR | insertion | Frame_Shift_Ins | novel | c.1226_1227insGGGAAGTGACTGCCAAGTTGAAGTTAGGAGTG | p.Phe409LeufsTer17 | p.F409Lfs*17 | P06213 | protein_coding | | | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
INSR | deletion | Frame_Shift_Del | novel | c.2222delN | p.Phe741SerfsTer30 | p.F741Sfs*30 | P06213 | protein_coding | | | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | Metformin glycinate | | 22974412 |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | agonist | CHEMBL1201644 | INSULIN ZINC SUSP RECOMBINANT HUMAN | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | agonist | CHEMBL1201638 | INSULIN SUSP PROTAMINE ZINC PURIFIED PORK | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | ILORASERTIB | ILORASERTIB | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | agonist | CHEMBL1201639 | INSULIN ZINC SUSP BEEF | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | agonist | CHEMBL1201496 | INSULIN ASPART | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | inhibitor | BMS-754807 | BMS-754807 | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | CENISERTIB | CENISERTIB | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | Insulin-lispro | | |
3643 | INSR | CLINICALLY ACTIONABLE, TYROSINE KINASE, EXTERNAL SIDE OF PLASMA MEMBRANE, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, ENZYME, DRUGGABLE GENOME | | AEW-541 | AEW-541 | |